Insider Transactions in Q3 2021 at Lumos Pharma, Inc. (LUMO)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+1.35%
|
$110,000
$11.21 P/Share
|
|
Sep 08
2021
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-6.66%
|
$24,354
$11.3 P/Share
|
|
Sep 07
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+1.37%
|
$110,000
$11.11 P/Share
|
|
Sep 03
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
8,100
+1.13%
|
$89,100
$11.35 P/Share
|
|
Sep 02
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,300
+0.89%
|
$69,300
$11.23 P/Share
|
|
Sep 01
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
4,589
+0.66%
|
$45,890
$10.87 P/Share
|
|
Aug 31
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,000
+0.86%
|
$60,000
$10.7 P/Share
|
|
Aug 30
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
8,625
+1.24%
|
$86,250
$10.52 P/Share
|
|
Aug 27
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
4,981
+0.73%
|
$49,810
$10.5 P/Share
|
|
Aug 26
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
6,200
+0.91%
|
$62,000
$10.07 P/Share
|
|
Aug 25
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
14,900
+2.19%
|
$134,100
$9.87 P/Share
|
|
Aug 24
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
10,775
+1.63%
|
$96,975
$9.45 P/Share
|
|
Aug 23
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
37,800
+5.57%
|
$340,200
$9.58 P/Share
|
|
Aug 20
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
35,679
+5.58%
|
$285,432
$8.73 P/Share
|
|
Aug 19
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+3.4%
|
$160,000
$8.45 P/Share
|
|
Aug 18
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
28,870
+5.01%
|
$230,960
$8.73 P/Share
|
|
Aug 17
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
16,000
+2.99%
|
$128,000
$8.47 P/Share
|
|
Aug 16
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+5.81%
|
$217,000
$7.96 P/Share
|
|
Aug 13
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+6.17%
|
$217,000
$7.86 P/Share
|
|
Aug 12
2021
|
Kevin M. Lalande Director |
BUY
Open market or private purchase
|
Indirect |
31,000
+6.57%
|
$217,000
$7.55 P/Share
|
|
Aug 12
2021
|
Aaron Schuchart Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+35.89%
|
$11,900
$7.42 P/Share
|
|
Aug 11
2021
|
Joseph S Mc Cracken Director |
BUY
Open market or private purchase
|
Direct |
7,475
+46.64%
|
$52,325
$7.55 P/Share
|
|
Aug 11
2021
|
Aaron Schuchart Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
300
+18.33%
|
$2,100
$7.35 P/Share
|
|
Aug 01
2021
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+28.99%
|
-
|
|
Aug 01
2021
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+37.58%
|
-
|